Future studies on targeted CSC therapy can focus more on K19, CD90, CD44, Toll-like receptors 4 (TLR4), SRY-related HMG-box gene 12 (SOX12), and aldehyde dehydrogenase (ALDH) to inhibit tumor metastasis. This evidence concerns the gene CD44 and neoplasm.